

**SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 04/18/17**

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	Reduce the risk of major adverse cardiac events (MACE) in patients with Chronic Heart Failure and significant Coronary Artery Disease (2)	Phase III	
		Prevention of Symptomatic VTE and VTE-related death in high-risk, medically ill pts (2)	Phase III	
		Secondary prevention of stroke in patients who have experienced Embolic Stroke of undetermined source (ESUS) (2)	Phase III	
		Reduce the risk of MACE in patients with coronary or Peripheral Artery Disease (2)	Phase III	
		VTE prophylaxis in ambulatory cancer patients receiving chemo at high-risk for VTE (2)	Phase III	
		Long-term Prevention of Recurrent Symptomatic VTE (2)	Phase III	
	INVOKANA® (canagliflozin)	Diabetic Nephropathy (2) Reduce the risk of death in type 2 diabetes with established, or risk for, cardiovascular disease. (CANVAS /CANVAS-R ) (2)	Phase III Phase III/IV	Phase III Phase III/IV
Immunology	guselkumab	Moderate to Severe Plaque Psoriasis	Filed 11/16	Filed 11/16
	SIMPONI® ARIA™ (golimumab)	Ankylosing spondylitis Psoriatic arthritis Juvenile Idiopathic Arthritis (JIA)	Filed 12/16 Filed 12/16 Phase III	
	sirukumab	Rheumatoid Arthritis (2)	Filed 9/16	Filed 9/16
	STELARA® (ustekinumab)	Pediatric Psoriasis Ulcerative Colitis Axial Spondylitis	Filed 12/16 Phase III Phase III	Approved 6/15 Phase III Phase III
Infectious Diseases and Vaccines	DARUNAVIR STR (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)	Single tablet regimen for HIV in treatment naïve patients and treatment experienced patients (2)	Phase III	Filed 9/16
	EDURANT® STR (rilpivirine and dolutegravir) Rilpivirine Long Acting nanosuspension for injection	Single tablet regimen for HIV in treatment experienced patients (2) HIV Infection	Phase III Phase III	Phase III Phase III
Neuroscience	esketamine	treatment-resistant depression	Phase III	Phase III
Oncology	DARZALEX®	Relapsed/refractory multiple myeloma in combination with lenalidomide/dexamethasone (MMY3003) (2)	Approved 11/16	Positive CHMP opinion 2/17
		Relapsed/refractory multiple myeloma in combination with bortezomib/dexamethasone (MMY3004) (2)	Approved 11/16	Positive CHMP opinion 2/17
		Frontline multiple myeloma transplant eligible in combination with bortezomib, thalidomide and dexamethasone (MMY 3006) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with bortezomib, melphalan, and prednisone (MMY 3007) (2)	Phase III	Phase III
		Frontline multiple myeloma transplant ineligible patients in combination with lenalidomide and low dose dexamethasone (MMY 3008) (2)	Phase III	Phase III
	IMBRUVICA® (ibrutinib)	Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (randomized study MCL-3002) (2)	Phase III	Phase III
		Relapsed/refractory patients with Indolent Non-Hodgkins Lymphoma in combination with Bendamustine and Rituximab or R-CHOP; (randomized study FLR-3001) (2)	Phase III	Phase III
		Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma in combination with R-CHOP (randomized study DBL3001) (2)	Phase III	Phase III
		Previously Treated Adults with Waldenström's Macroglobulinemia with Rituximab (PCYC-1127) (2)	Phase III	Phase III
		Frontline Chronic Lymphocytic Leukemia (Young and Fit) (in combination with Rituximab) (ECOG 1912) (2)	Phase III	Phase III
		Marginal Zone Lymphoma in patients who require systemic therapy and have received at least one prior anti-CD20- based therapy. (PCYC-1121) (2)	Approved 1/17	
	apalutamide (ARN-509)	Chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy (2)	Filed 2/17	
		Frontline Chronic Lymphocytic Leukemia in combination with obinutuzumab (PCYC-1130) (2)	Phase III	Phase III
apalutamide (ARN-509)	Prostate cancer pre-metastatic castration-resistant Metastatic hormone sensitive prostate cancer Localized prostate cancer	Phase III Phase III Phase III	Phase III Phase III Phase III	
	apalutamide (ARN-509) / ZYTIGA® (abiraterone acetate)	Prostate Cancer metastatic castration resistant chemotherapy naïve	Phase III	Phase III
YONDELIS® (trabectedin)	Relapsed Ovarian Cancer (2)	Phase III		
ZYTIGA® (abiraterone acetate)	Prostate Cancer Newly Diagnosed Hormone Naïve Metastatic		Filed 4/17	

\* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) INVOKANA licensed from Mitsubishi Tanabe Pharma Corporation; PREZISTA STR and EDURANT STR (R/F/TAF) developed in collaboration with Gilead Sciences; EDURANT STR developed in collaboration with ViV Healthcare; YONDELIS developed in collaboration with PharmaMar S.A.;

XARELTO co-developed with Bayer HealthCare; INVEGA SUSTENNA includes technology licensed from Alkermes, Inc.; DARZALEX licensed from Genmab A/S; IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; Sirukumab developed in collaboration with GlaxoSmithKline.